Real‐world experience of axicabtagene ciloleucel, a CD19‐directed CAR T‐cell therapy, in the second‐line treatment of early relapsed or primary refractory large B‐cell lymphoma-Reference-Cited by-同舟云学术

Real‐world experience of axicabtagene ciloleucel, a CD19‐directed CAR T‐cell therapy, in the second‐line treatment of early relapsed or primary refractory large B‐cell lymphoma

Published:2024-05-26 Issue:1 Volume:205 Page:368-372
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Othman Tamer¹^ORCID,Baird John H.¹^ORCID,Pak Stacy²,Mei Matthew¹^ORCID,Herrera Alex F.¹^ORCID,Mansour Joshua¹,Shouse Geoffrey¹,Sahebi Firoozeh¹³^ORCID,Spielberger Ricardo¹³,Cai Ji‐Lian¹³,Farol Leonardo¹³,Godfrey James¹,Kallam Avyakta¹,Phillips Tycel¹,Popplewell Leslie⁴,Siddiqi Tanya¹,Forman Stephen¹,Budde Lihua E.¹^ORCID

Affiliation:

1. Department of Hematology and Hematopoietic Cell Transplantation City of Hope Duarte California USA

2. Department of Pharmacy City of Hope National Medical Center Duarte California USA

3. Kaiser Permanente Los Angeles California USA

4. Department of Hematology and Hematopoietic Cell Transplantation City of Hope Atlanta Georgia USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19521

Reference6 articles.

1. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023

2. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

3. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

4. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy

5. Immune effector cell–associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes